2020
Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice
Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice. Ophthalmology 2020, 128: 417-424. PMID: 32781110, DOI: 10.1016/j.ophtha.2020.07.062.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsBevacizumabCerebrovascular DisordersDrug-Related Side Effects and Adverse ReactionsFemaleHemorrhageHospitalizationHumansIntravitreal InjectionsMaleMyocardial InfarctionRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRetinal DiseasesRetrospective StudiesRisk AssessmentVascular Endothelial Growth Factor AConceptsNeovascular age-related macular degenerationRetinal venous occlusive diseaseDiabetic retinal diseaseSystemic serious adverse eventsAnti-VEGF injectionsAnti-VEGF agentsMajor bleedingAcute myocardial infarctionCause hospitalizationCerebrovascular diseaseRoutine clinical practiceMyocardial infarctionIntravitreal bevacizumabTreatment initiationAdverse eventsPropensity score-weighted Cox proportional hazards modelClinical practiceLarge U.S. administrative claims databaseRisk of MICox proportional hazards modelU.S. administrative claims databaseAge-related macular degenerationRisk-adjusted effectSystemic safety profileRetrospective cohort study
2019
Follow-up Care for Breast Cancer Survivors
Ruddy KJ, Herrin J, Sangaralingham L, Freedman RA, Jemal A, Haddad TC, Allen SV, Hieken T, Boughey JC, Ganz PA, Havyer RD, Shah ND. Follow-up Care for Breast Cancer Survivors. Journal Of The National Cancer Institute 2019, 112: 111-113. PMID: 31613369, PMCID: PMC7849972, DOI: 10.1093/jnci/djz203.Peer-Reviewed Original ResearchConceptsBreast cancer survivorsCancer survivorsUS commercial insurance databaseCurative-intent surgeryCommercial insurance databasePrimary care providersEndocrine therapyIntent surgeryImpairs outcomeSurvivorship guidelinesInsurance databaseNonwhite raceAnnual followBreast cancerCare providersClaims dataClinical practiceOlder ageSurgeryWomenSurvivorsYear 2ChemotherapyPatientsOncologists
2018
Risk of Systemic Adverse Events Associated with Intravitreal Anti–VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice
Maloney MH, Schilz SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ. Risk of Systemic Adverse Events Associated with Intravitreal Anti–VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice. Ophthalmology 2018, 126: 1007-1015. PMID: 30292542, DOI: 10.1016/j.ophtha.2018.09.040.Peer-Reviewed Original ResearchConceptsDiabetic macular edemaRoutine clinical practiceSystemic serious adverse eventsMacular laserMajor bleedingCerebrovascular diseaseMyocardial infarctionClinical practiceCause hospitalizationAdverse eventsHazard ratioIntravitreal corticosteroidsAnti-VEGFMacular edemaDME treatmentTreatment of DMEIntravitreal anti-VEGF therapyCox proportional hazards regressionAnti-VEGF pharmacotherapySystemic safety profileCorticosteroid-treated patientsRetrospective cohort studySerious adverse eventsSystemic adverse eventsMacular laser photocoagulation
2017
The Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast Cancer
Pollack CE, Soulos PR, Herrin J, Xu X, Christakis NA, Forman HP, Yu JB, Killelea BK, Wang SY, Gross CP. The Impact of Social Contagion on Physician Adoption of Advanced Imaging Tests in Breast Cancer. Journal Of The National Cancer Institute 2017, 109: djw330. PMID: 28376191, PMCID: PMC6059114, DOI: 10.1093/jnci/djw330.Peer-Reviewed Original ResearchConceptsMagnetic resonance imagingBaseline usePositron emission tomography scanEnd Results-MedicareEmission tomography scanBreast cancer practiceImaging modalitiesAdvanced imaging testsHierarchical logistic regression modelsLogistic regression modelsPatient characteristicsUnproven benefitCancer practiceMRI/PETTomography scanBreast cancerMRI useImaging testsClinical practicePET useResonance imagingPET imagingPhysician peersPhysician adoptionBaseline period
2012
Patterns of Use and Short-Term Complications of Breast Brachytherapy in the National Medicare Population From 2008–2009
Presley CJ, Soulos PR, Herrin J, Roberts KB, Yu JB, Killelea B, Lesnikoski BA, Long JB, Gross CP. Patterns of Use and Short-Term Complications of Breast Brachytherapy in the National Medicare Population From 2008–2009. Journal Of Clinical Oncology 2012, 30: 4302-4307. PMID: 23091103, PMCID: PMC3675700, DOI: 10.1200/jco.2012.43.5297.Peer-Reviewed Original ResearchConceptsWhole breast irradiationHospital referral regionsBone complicationsClinical characteristicsSkin complicationsEarly-stage breast cancerNational treatment patternsPercent of patientsShort-term complicationsBreast-conserving surgeryNational Medicare populationComplication rateTreatment patternsAge 66Breast cancerReferral regionsMedicare populationPatterns of useComplicationsMedicare beneficiariesTreatment groupsClinical practiceBreast brachytherapyBrachytherapyInstrumental variable analysisShort-term complications and use of breast brachytherapy in the national Medicare population in 2008-2009.
Presley C, Soulos P, Herrin J, Roberts K, Yu J, Killelea B, Lesnikoski B, Long J, Gross C. Short-term complications and use of breast brachytherapy in the national Medicare population in 2008-2009. Journal Of Clinical Oncology 2012, 30: 1030-1030. DOI: 10.1200/jco.2012.30.15_suppl.1030.Peer-Reviewed Original ResearchWhole breast irradiationHospital referral regionsBone complicationsClinical characteristicsSkin complicationsReferral regionsEarly-stage breast cancerNational treatment patternsOne-year overallReceipt of chemotherapyNumber of comorbiditiesShort-term complicationsDeep tissuesNational Medicare populationAdjuvant radiationComplication rateTreatment patternsDiagnosis codesBreast cancerMedicare claimsMedicare populationComplicationsMedicare beneficiariesTreatment groupsClinical practiceAssessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population
Soulos PR, Yu JB, Roberts KB, Raldow AC, Herrin J, Long JB, Gross CP. Assessing the Impact of a Cooperative Group Trial on Breast Cancer Care in the Medicare Population. Journal Of Clinical Oncology 2012, 30: 1601-1607. PMID: 22393088, PMCID: PMC3383112, DOI: 10.1200/jco.2011.39.4890.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBreast NeoplasmsCombined Modality TherapyDisease-Free SurvivalFemaleHumansLife ExpectancyMastectomy, SegmentalMedicareNeoplasm InvasivenessNeoplasm StagingPrognosisRadiotherapy, AdjuvantRisk AssessmentSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsUse of RTAdjuvant radiation therapyRadiation therapyOlder womenRT useLife expectancyBreast cancerMedicare populationEnd Results-Medicare dataStage I breast cancerStrata of ageCooperative group trialsI breast cancerBreast cancer careStrata of patientsHealth system characteristicsLog-binomial regressionShort life expectancySample of womenTreatment guidelinesCancer careInclusion criteriaGroup trialsMedicare beneficiariesClinical practice
2001
Continuing education meetings and workshops: effects on professional practice and health care outcomes
O'Brien M, Freemantle N, Oxman A, Wolfe F, Davis D, Herrin J. Continuing education meetings and workshops: effects on professional practice and health care outcomes. 2001, cd003030. PMID: 11406063, DOI: 10.1002/14651858.cd003030.Peer-Reviewed Original ResearchConceptsHealth care outcomesCare outcomesHealth professionalsEducational meetingsCochrane Effective PracticeDevelopment Resource BaseEducation meetingsDATA COLLECTIONCare groupImproved health careBaseline complianceInclusion criteriaOutcome measuresReference listsClinical practiceQuasi-experimental studyDidactic presentationsHealth careInteractive workshopCommon typeContinuing Medical EducationDidactic sessionsInterventionOutcomesStudy data